Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Unigene Laboratories, engaged in designing, delivering, manufacturing and developing of peptide-based therapeutics, has reported a revenue of $2.47m for the second quarter ended 30 June 2011, compared to $3.03m for the same period in 2010.
Subscribe to our email newsletter
Unigene’s net loss was $8.44m, or $0.09 loss per diluted share, compared to net loss of $3.64m, or $0.04 loss per diluted share, for the same period in 2010.
The company’s operating loss for the second quarter of 2011 was $3.07m, compared to operating loss of $3m for the same period in 2010.
For the six months ended 30 June 2011, the company reported revenue of $4.59m, compared to $5.56m for the same period in 2010.
The company has reported net loss of $15.08m or 0.16 loss per diluted share for the six months ended 30 June 2011, as compared to $19.59m or $0.21 loss per diluted share for the same period in 2010.
Unigene’s operating loss was $6.7m for the six months of 2011, compared to $5.8m for the same period in 2010.